These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 36034448

  • 1. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X.
    Front Endocrinol (Lausanne); 2022; 13():922304. PubMed ID: 36034448
    [Abstract] [Full Text] [Related]

  • 2. Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial.
    Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F, Cheng R.
    Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetic/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals.
    Cheng R, Zhao Q, Zhong G, Xu J, Zheng Z, Xi L, Zhang M, Ni J, Hu P, Luo F, Lu W.
    Eur J Pharm Sci; 2022 Dec 01; 179():106304. PubMed ID: 36209987
    [Abstract] [Full Text] [Related]

  • 4. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, Gong CX, Li Y, Du ML, Su Z, Du H, Yan C.
    Eur J Endocrinol; 2017 Aug 01; 177(2):195-205. PubMed ID: 28566441
    [Abstract] [Full Text] [Related]

  • 5. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
    Sävendahl L, Battelino T, Brod M, Højby Rasmussen M, Horikawa R, Juul RV, Saenger P, REAL 3 study group.
    J Clin Endocrinol Metab; 2020 Apr 01; 105(4):e1847-61. PubMed ID: 31917835
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan 01; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study.
    Xie L, Li Y, Zhang J, Guo S, Chen Q, Ma H, Jiang W.
    Eur J Pediatr; 2024 Oct 01; 183(10):4531-4539. PubMed ID: 39158594
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study.
    Hou L, Lin S, Liu Z, Zhang L, Ou H, Huang S, Dai H, Meng Z, Liang L.
    J Pediatr Endocrinol Metab; 2024 Oct 28; 37(10):892-899. PubMed ID: 39190198
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016 Oct 28; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 12. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study.
    Jiang Z, Chen X, Dong G, Lou Y, Zhang J, Cheng X, Pan J, Liao W, Wu J, Huang X, Jin X, Liu D, Zeng T, Zhu S, Dong Q, Luo X, Lan D, Cao L, Zhang X, Liu J, Dai M, Zhang M, Liu L, Dong J, Zhao D, Ni S, Fu J.
    Front Pharmacol; 2022 Oct 28; 13():955809. PubMed ID: 36034802
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E, Klose M, Hansen M, Hansen BS, Andersen M, Feldt-Rasmussen U, Laursen T, Rasmussen MH, Christiansen JS.
    J Clin Endocrinol Metab; 2011 Mar 28; 96(3):681-8. PubMed ID: 21177789
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.
    Owada Y, Okazaki M, Ikeda T, Yamamoto R, Minami K, Takahashi K, Hirato T, Mita Y, Yamamoto T, Tanizawa K, Sonoda H, Sato Y.
    Growth Horm IGF Res; 2022 Dec 28; 67():101500. PubMed ID: 36113378
    [Abstract] [Full Text] [Related]

  • 16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
    Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR.
    Endocr Pract; 2019 Nov 28; 25(11):1191-1232. PubMed ID: 31760824
    [Abstract] [Full Text] [Related]

  • 17. Long-acting PEGylated growth hormone in children with idiopathic short stature.
    Luo X, Zhao S, Yang Y, Dong G, Chen L, Li P, Luo F, Gong C, Xu Z, Xu X, Gong H, Du H, Hou L, Zhong Y, Shi Q, Chen X, Chen X, Xu L, Cheng R, Su C, Ma Y, Xu L, Zhang L, Lu H.
    Eur J Endocrinol; 2022 Nov 01; 187(5):709-718. PubMed ID: 36130048
    [Abstract] [Full Text] [Related]

  • 18. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Sävendahl L, NN8640-4042 Study Group.
    Clin Endocrinol (Oxf); 2017 Oct 01; 87(4):350-358. PubMed ID: 28656605
    [Abstract] [Full Text] [Related]

  • 19. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment.
    Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, Valluri SR, Pastrak A, Rosenfeld R.
    J Pediatr Endocrinol Metab; 2023 Mar 28; 36(3):261-269. PubMed ID: 36732285
    [Abstract] [Full Text] [Related]

  • 20. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A, Rogol AD, Elsiddig S, Khalil A, Alaaraj N, Alyafie F, Ahmed H, Elawwa A.
    J Pediatr Endocrinol Metab; 2021 Oct 26; 34(10):1263-1271. PubMed ID: 34291621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.